KROS Jun 2024 75.000 put
- GlobeNewswire
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the Europ
- GuruFocus.com
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
- GlobeNewswire
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
